Acazicolcept (ALPN-101), an experimental therapy that blocks T-cell activation and is being developed by Alpine Immune Sciences, was found effective at decreasing scarring in mouse models of systemic sclerosis (SSc). A team of scientists at Alpine and other institutions published their findings in a study, “…
News
The U.S. Food and Drug Administration (FDA) has approved a clinical trial to determine the safety and efficacy of adipose-derived regenerative cells (ADRCs) for the treatment of hand dysfunction in patients with diffuse cutaneous scleroderma, Paracrine has announced. The Phase 3 trial, called STAR…
Slowing the decline in lung function, even small reductions, may prevent hospitalizations in patients with interstitial lung disease associated with systemic sclerosis (SSc-ILD), according to a post-hoc analysis of the Phase 3 SENSCIS trial. Researchers found that a greater decline in lung function is significantly associated with an…
When gene expression — the process in which a gene gets turned ‘on’ in a cell to make proteins — is dysregulated or does not function the way it should normally, the affected skin of patients with systemic sclerosis (SSc) tends to be abnormally thicker, a study has found.
The Scleroderma Research Foundation (SRF) will match every dollar donated in honor of the late comedian Bob Saget — a 30-year board member — up to $1.5 million. The matching gift was donated by fellow board members Luke Evnin, PhD, and Deann Wright after family, friends, and fans sought…
The Scleroderma Foundation is relaunching itself under a new name, the National Scleroderma Foundation, intending to reach and educate a larger audience and connect more of those affected by scleroderma with the resources they need. “The scope of our work is nationwide,” Mary Wheatley, CEO of the National…
People with systemic sclerosis (SSc) in Brazil had a weaker immune response to the CoronaVac COVID-19 vaccine than did healthy individuals, a study discovered. The findings also showed that treatment with the immunosuppressant therapy CellCept (mycophenolate mofetil) — an oral medication that improves lung function in SSc patients…
Several risk factors for diastolic dysfunction (DD), the heart’s inability to fill with blood properly after it beats, were identified in people with systemic sclerosis (SSc) in a recent study. These risk factors, such as obesity, could be potentially modified to reduce the occurrence of more serious disease outcomes,…
Cantargia’s investigational antibody treatment, CAN10, showed promise in an animal model of systemic sclerosis (or scleroderma), normalizing several biological indicators of disease and counteracting disease development in the skin and lungs. “We are excited about these new results, showing strong effects of CAN10 in a systemic sclerosis model.
People with sine sclerosis — a rare form of scleroderma without skin involvement — have better survival than those with limited and diffuse scleroderma, according to a retrospective study of up to 18 years of patient data. In addition, male sex, poor lung function, heart involvement, and…
Recent Posts
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma